Home 9 Members 9 Workshop 9 Surgical Management of Primary Cutaneous Melanoma

Surgical Management of Primary Cutaneous Melanoma

UK Guidelines on the Management of Primary Cutaneous Malignant Melanoma

  1. Diagnostic Biopsy. Where practicable total excision biopsies should be undertaken. Exceptions include significant doubt about the diagnosis, some anatomical sites and very large lesions such as lentigo maligna where doubt exists about diagnosis. The reason for total biopsy is a) to avoid sampling error and b) to enable optimum treatment to be based on thorough histological examination of the entire specimen.
  2. Therapeutic Excision.

All margins are measured at the time of surgery from the clinical edge of the lesion.

In Situ and Horizontal Growth Phase excise 2 – 5 mm around clinical edge.

Vertical Growth Phase

Breslow thickness

Margin

0.0 to 0.75 mm

5mm

0.75mm to 1.0mm

10mm

1mm to 2mm

10 to 20mm

2mm to 4mm

20 to 30mm (20mm preferred)

Greater than 4mm

20 to 30mm

 

Staging should be undertaken for tumours that are stage 2B or above i.e. tumours greater than 2mm thick with ulceration or greater than 4mm thick without ulceration.

Staging investigations (Appendix A)

For Stage 2A

  • Full Blood Count
  • Liver Function Tests
  • Chest X-ray

For Stage 2B or above

  • Liver Ultrasound, or
  • CT scan with contrast of chest, abdomen and/or pelvis

Follow up

  1. All patients should be taught self examination of local skin and regional nodes.
  2. Patients with in situ (horizontal growth phase) tumours need be seen once only post operatively
  3. All patients with invasive melanoma (vertical growth phase) should be followed up three monthly for three years. Thereafter patients with tumours less than 1.0mm thick may be discharged and others reviewed six monthly for a further two years.
  4. At follow up the following examination should take place.
    1. Examination of primary site and surrounding skin by observation and palpation for local recurrence and local metastatic disease.
    2. The draining regional lymph nodes.
    3. The remaining skin noting any suspicious pigmented lesions (possibly photograph them)

Sentinel Node Biopsy

May be useful for staging patients with stage II melanoma in a specialist centre as part of a clinical trial.

 

Appendix A

AJCC/UICC staging system recommended.

STAGE

Primary tumour (pT)

Lymph Node (N)

Dist. Mets (M)

1A

pT1a

 

M0

1B

pT1b

N0

M0

 

pT2a

N0

M0

2A

pT2b

N0

M0

 

pT3a

N0

M0

2B

pT3b

N0

M0

 

pT4a

N0

M0

2C

pT4b

N0

M0

3A

Any pT

N0

M0

3B

Any pT

N1a

M0

3C

Any pT

N1b, N2a

M0

4

 

N2b, N3

M1, 2, or 3

Key to table

Primary

Breslow Thickness

pT1

<1.0mm

pT2

1.01 to 2.0mm

pT3

2.01 to 4.0mm

pT4

>4.0mm

   

Ulceration

 

Ta

no ulceration

Tb

ulceration present

   

Nodes

 

N0

No nodes involved

N1

One metastatic node

N2

2 to 4 nodes

N3

5 or more nodes

   

Nodal size

 

Na

Occult

Nb

palpable

 

Metastases

 

M1

Skin (in transit), subcutaneous or distant lymph nodes

M2

Lung

M3

All other sites or any site with raised LDH